JP2008513367A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008513367A5 JP2008513367A5 JP2007531313A JP2007531313A JP2008513367A5 JP 2008513367 A5 JP2008513367 A5 JP 2008513367A5 JP 2007531313 A JP2007531313 A JP 2007531313A JP 2007531313 A JP2007531313 A JP 2007531313A JP 2008513367 A5 JP2008513367 A5 JP 2008513367A5
- Authority
- JP
- Japan
- Prior art keywords
- apo2l
- antibody
- medicament according
- trail polypeptide
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 15
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 10
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229960004641 rituximab Drugs 0.000 claims 2
- 230000002195 synergetic effect Effects 0.000 claims 2
- 241000588724 Escherichia coli Species 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60790904P | 2004-09-08 | 2004-09-08 | |
| US66655305P | 2005-03-30 | 2005-03-30 | |
| PCT/US2005/031907 WO2006029224A2 (en) | 2004-09-08 | 2005-09-07 | Methods of using death receptor ligands and cd20 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008513367A JP2008513367A (ja) | 2008-05-01 |
| JP2008513367A5 true JP2008513367A5 (enExample) | 2008-11-13 |
Family
ID=35788048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007531313A Pending JP2008513367A (ja) | 2004-09-08 | 2005-09-07 | デスレセプターリガンド及びｃｄ２０抗体の使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20090317384A1 (enExample) |
| EP (1) | EP1791864A2 (enExample) |
| JP (1) | JP2008513367A (enExample) |
| KR (1) | KR20070050950A (enExample) |
| AU (1) | AU2005282440A1 (enExample) |
| BR (1) | BRPI0515615A (enExample) |
| CA (1) | CA2577823A1 (enExample) |
| IL (1) | IL181316A0 (enExample) |
| MX (1) | MX2007002855A (enExample) |
| NO (1) | NO20071790L (enExample) |
| NZ (1) | NZ553174A (enExample) |
| RU (1) | RU2007112929A (enExample) |
| WO (1) | WO2006029224A2 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7348003B2 (en) | 2001-05-25 | 2008-03-25 | Human Genome Sciences, Inc. | Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors |
| US7361341B2 (en) | 2001-05-25 | 2008-04-22 | Human Genome Sciences, Inc. | Methods of treating cancer using antibodies that immunospecifically bind to trail receptors |
| RS54450B1 (sr) | 2003-11-05 | 2016-06-30 | Roche Glycart Ag | Molekuli koji se vezuju za antigen sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom |
| EP1756162A1 (en) | 2004-03-23 | 2007-02-28 | Biogen Idec MA Inc. | Receptor coupling agents and therapeutic uses thereof |
| GB0524316D0 (en) * | 2005-11-29 | 2006-01-04 | Medical Res Council | Tumour necrosis factor-related apoptosis-inducing ligands (TRAILs) |
| KR20090093959A (ko) * | 2006-10-23 | 2009-09-02 | 더 유에이비 리서치 파운데이션 | 항암제에 대한 감수성을 나타내는 암에 대한 생체마커 및 이의 용도 |
| JPWO2009020093A1 (ja) * | 2007-08-09 | 2010-11-04 | 第一三共株式会社 | デスドメイン含有受容体発現細胞にアポトーシスを誘導するイムノリポソーム |
| TW201438738A (zh) | 2008-09-16 | 2014-10-16 | 建南德克公司 | 治療進展型多發性硬化症之方法 |
| WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
| WO2011028961A2 (en) | 2009-09-04 | 2011-03-10 | Xoma Technology Ltd. | Anti-botulism antibody coformulations |
| EP2473191B1 (en) * | 2009-09-04 | 2017-08-23 | XOMA Technology Ltd. | Antibody coformulations |
| AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| US9173961B2 (en) | 2010-02-10 | 2015-11-03 | Immunogen, Inc. | CD20 antibodies and uses thereof |
| CA2834776A1 (en) * | 2011-05-03 | 2012-11-08 | Genentech, Inc. | Therapeutic apo2l/trail polypeptides and death receptor agonist antibodies |
| WO2015138638A1 (en) | 2014-03-11 | 2015-09-17 | Theraly Pharmaceuticals, Inc. | Long acting trail receptor agonists for treatment of autoimmune diseases |
| US10501552B2 (en) | 2015-01-26 | 2019-12-10 | Macrogenics, Inc. | Multivalent molecules comprising DR5-binding domains |
| WO2017106627A1 (en) | 2015-12-17 | 2017-06-22 | The Johns Hopkins University | Ameliorating systemic sclerosis with death receptor agonists |
| EP3439687A1 (en) | 2016-04-07 | 2019-02-13 | The Johns Hopkins University | Compositions and methods for treating pancreatitis and pain with death receptor agonists |
| EP4252629A3 (en) | 2016-12-07 | 2023-12-27 | Biora Therapeutics, Inc. | Gastrointestinal tract detection methods, devices and systems |
| US20210138213A1 (en) | 2017-03-30 | 2021-05-13 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
| KR102532779B1 (ko) * | 2017-09-08 | 2023-05-16 | 한국생명공학연구원 | Ddias 억제제 및 사멸 수용체 리간드를 포함하는 암의 예방 또는 치료용 조성물 |
| US12227565B2 (en) | 2018-06-20 | 2025-02-18 | Biora Therapeutics, Inc. | Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine |
| US20230041197A1 (en) | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| JP7482866B2 (ja) | 2018-11-19 | 2024-05-14 | ビオラ・セラピューティクス・インコーポレイテッド | 生物学的治療薬による疾患処置方法およびデバイス |
| CN121197633A (zh) | 2019-12-13 | 2025-12-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| US11767353B2 (en) | 2020-06-05 | 2023-09-26 | Theraly Fibrosis, Inc. | Trail compositions with reduced immunogenicity |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) * | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5736137A (en) * | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| ATE285475T1 (de) * | 1994-02-04 | 2005-01-15 | Bio Merieux | Msrv1 virus der mit multipler sklerose verbunden ist, seine nukleären bestandteile und verwendungen |
| DE69635480T2 (de) * | 1995-06-29 | 2006-08-17 | Immunex Corp., Thousand Oaks | Apoptosis induzierendes cytokin |
| US6030945A (en) * | 1996-01-09 | 2000-02-29 | Genentech, Inc. | Apo-2 ligand |
| US6998116B1 (en) * | 1996-01-09 | 2006-02-14 | Genentech, Inc. | Apo-2 ligand |
| WO1998032856A1 (en) * | 1997-01-28 | 1998-07-30 | Human Genome Sciences, Inc. | Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap02-l) |
| US6433147B1 (en) * | 1997-01-28 | 2002-08-13 | Human Genome Sciences, Inc. | Death domain containing receptor-4 |
| US6072047A (en) * | 1997-02-13 | 2000-06-06 | Immunex Corporation | Receptor that binds trail |
| US20020160446A1 (en) * | 2000-11-14 | 2002-10-31 | Holtzman Douglas A. | Novel genes encoding proteins having prognostic diagnostic preventive therapeutic and other uses |
| US20010010924A1 (en) * | 1997-03-14 | 2001-08-02 | Keith Charles Deen | Tumor necrosis factor related receptor, tr6 polynecleotides |
| US6872568B1 (en) * | 1997-03-17 | 2005-03-29 | Human Genome Sciences, Inc. | Death domain containing receptor 5 antibodies |
| AU747635B2 (en) * | 1997-03-17 | 2002-05-16 | Human Genome Sciences, Inc. | Death domain containing receptor 5 |
| AU7126498A (en) * | 1997-04-16 | 1998-11-11 | Millennium Pharmaceuticals, Inc. | Tumor necrosis factor receptor related proteins tango-63d and tango-63e |
| US6342369B1 (en) * | 1997-05-15 | 2002-01-29 | Genentech, Inc. | Apo-2-receptor |
| JPH11162958A (ja) * | 1997-09-16 | 1999-06-18 | Tokyo Electron Ltd | プラズマ処理装置及びその方法 |
| US6252050B1 (en) * | 1998-06-12 | 2001-06-26 | Genentech, Inc. | Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method |
| CA2702192A1 (en) * | 2001-03-14 | 2002-09-19 | Genentech, Inc. | Igf antagonist peptides |
| EP2348043A1 (en) * | 2001-10-02 | 2011-07-27 | Genentech, Inc. | APO-2 ligand variants and uses thereof |
| AU2002360307B2 (en) * | 2001-11-01 | 2008-01-17 | The Uab Research Foundation | Combinations of DR5 antibody and other therapeutic agents |
| AU2002346373A1 (en) * | 2001-11-09 | 2003-05-19 | Idec Pharmaceuticals Corporation | Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies |
| AU2003247609A1 (en) * | 2002-06-24 | 2004-01-06 | Genentech, Inc. | Apo-2 ligand/trail variants and uses thereof |
-
2005
- 2005-09-07 US US11/662,314 patent/US20090317384A1/en not_active Abandoned
- 2005-09-07 AU AU2005282440A patent/AU2005282440A1/en not_active Abandoned
- 2005-09-07 JP JP2007531313A patent/JP2008513367A/ja active Pending
- 2005-09-07 NZ NZ553174A patent/NZ553174A/en not_active IP Right Cessation
- 2005-09-07 CA CA002577823A patent/CA2577823A1/en not_active Abandoned
- 2005-09-07 EP EP05794923A patent/EP1791864A2/en not_active Withdrawn
- 2005-09-07 BR BRPI0515615-7A patent/BRPI0515615A/pt not_active IP Right Cessation
- 2005-09-07 MX MX2007002855A patent/MX2007002855A/es not_active Application Discontinuation
- 2005-09-07 KR KR1020077005374A patent/KR20070050950A/ko not_active Withdrawn
- 2005-09-07 WO PCT/US2005/031907 patent/WO2006029224A2/en not_active Ceased
- 2005-09-07 RU RU2007112929/13A patent/RU2007112929A/ru not_active Application Discontinuation
-
2006
- 2006-10-03 US US11/542,528 patent/US20080044421A1/en not_active Abandoned
-
2007
- 2007-02-13 IL IL181316A patent/IL181316A0/en unknown
- 2007-04-04 NO NO20071790A patent/NO20071790L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008513367A5 (enExample) | ||
| RU2007112929A (ru) | Способы применения лигандов рецептора смерти и антител к cd20 | |
| Li et al. | Effects of Th2 cytokines on chemokine expression in the lung: IL-13 potently induces eotaxin expression by airway epithelial cells | |
| Hashizume et al. | Tocilizumab, a humanized anti-interleukin-6 receptor antibody, improved anemia in monkey arthritis by suppressing IL-6-induced hepcidin production | |
| EP4559934A2 (en) | Pharmaceutical products and stable liquid compositions of il-17 antibodies | |
| US11779631B2 (en) | CD47 blockade therapy by HDAC inhibitors | |
| CN109789196A (zh) | 用于通过施用il-4r拮抗剂来预防或治疗变态反应的方法 | |
| EP1921090A4 (en) | COMPOSITION OF GENETICALLY MODIFIED ANTIBODY | |
| JP2009519257A5 (enExample) | ||
| JP2010518079A5 (enExample) | ||
| JP2015520188A5 (enExample) | ||
| JP2021193121A (ja) | Ｉｌ−１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法 | |
| US20200237822A1 (en) | Compositions and methods for stimulating natural killer cells | |
| ES2860480T3 (es) | Anticuerpos neutralizantes de GM-CSF para su uso en el tratamiento de la artritis reumatoide o como analgésicos | |
| Amini-Vaughan et al. | Therapeutic strategies for harnessing human eosinophils in allergic inflammation, hypereosinophilic disorders, and cancer | |
| US20250333522A1 (en) | Compositions and methods for treating pain in subjects with rheumatoid arthritis | |
| TW202225190A (zh) | 用於治療嗜中性球性皮膚病之抗-il-36r抗體 | |
| EP4268803A1 (en) | Stable antibody preparation, preparation method for same, and applications thereof | |
| CN116406290A (zh) | 用于治疗慢性炎症性疼痛的抗il-36r抗体 | |
| AU2019235627B2 (en) | Improvements in CD47 blockade therapy by EGFR antibody | |
| JP2014526440A5 (enExample) | ||
| TW202208433A (zh) | 用於治療異位性皮膚炎之抗ｉｌ－３６ｒ抗體 | |
| Weigelt et al. | Pharmacokinetic evaluation of palifermin for mucosal protection from chemotherapy and radiation | |
| ES2239814T3 (es) | Metodo de movilizacion de celulas madre hematopoyeticas. | |
| RU2420308C2 (ru) | Стабилизированные композиции ил-21 |